Vincerx Inc News - VINC | ADVFN

Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

Get Started

Vincerx Inc (VINC)

0.252

-0.004

(-1.56%)

Closed November 23 4:00PM

Delayed by 15 minutes

0.2531

0.0011

(0.44%)

After Hours: 7:40PM

Delayed by 15 minutes

Professional-Grade Tools, for Individual Investors.

Form 8-K - Current report

Vincerx Pharma Reports Third Quarter 2024 Financial Results

Continued enrollment and dose escalation in Phase 1 study of VIP943, a potentially best-in-class anti-CD123...

Form PRE 14A - Other preliminary proxy statements

Vincerx Reports Positive Initial Clinical Data from Ongoing VIP943 Phase 1 Dose-Escalation Study and Provides Pipeline and Corporate Updates

VIP943 demonstrates promising safety and tolerability and achieves two complete responses to date in Phase 1...

Form SC TO-I/A - Tender offer statement by Issuer: [Amend]

Form SC TO-I/A - Tender offer statement by Issuer: [Amend]

Form SC TO-I/A - Tender offer statement by Issuer: [Amend]

Form 8-K - Current report

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form SC TO-I - Tender offer statement by Issuer

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Vincerx Pharma Reports Second Quarter 2024 Financial Results

Vincerx continues to enroll its Phase 1 studies of antibody-drug conjugate (ADC) VIP943, with data expected by...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

1
Next

tw0122

tw0122 2 months ago

VINC .84 + 20% …05:05 PM EDT, 10/07/2024 (MT Newswires) -- Vincerx Pharma (VINC) said its VIP943 leukemia drug showed "promising safety and tolerability," achieving two complete responses to date in a phase 1 dose-escalation study

The VIP943 antibody-drug conjugate is being evaluated in relapsed/refractory acute myeloid leukemia, higher-risk myelodysplastic syndrome and B-cell acute lymphoblastic leukemia, the company said Monday in a statement.

Another data update is expected by the end of the year, the company said.

In an update on VIP236 being evaluated in a first-in-human, phase 1 dose-escalation study as a monotherapy in patients with advanced solid tumors, the company said it intends to pursue a strategic partner to "champion its future development" in order to focus on VIP943.

Vincerx expects a cash runway into early 2025.

Shares of the company jumped 15% in after-hours activity.

Price: 0.8000, Change: +0.10, Percent Change: +

Laster

Laster 7 months ago

What a cluster this stock has become.
Unreal actually. $0.60 to $10 back to $0.60 all within 4 months.
Can’t believe they didn’t try to do the financing when it was trading above $5.

RAlbert

RAlbert 7 months ago

Tomorrow will be $1.50

RAlbert

RAlbert 7 months ago

No news on dilution yet. When will we see a rebound? Seeking money being lost is the painful part of life

RAlbert

RAlbert 7 months ago

Blood bath. I should have waited one more day.

Monksdream

Monksdream 7 months ago

Somebody knows something you don’t

RAlbert

RAlbert 7 months ago

I don’t find the price and volume the capital raise is. Am I missing anything here?

Monksdream

Monksdream 7 months ago

Check for SEC filings

RAlbert

RAlbert 7 months ago

Is the capital raise 80% discounted to yesterday price? Insane

Monksdream

Monksdream 7 months ago

Check for a capital raise which means dilution

RAlbert

RAlbert 7 months ago

Wonder why there is a steep fall in price when the results are not negative.

RAlbert

RAlbert 7 months ago

Wonder why there is a steep fall in price when the results are not negative.

Monksdream

Monksdream 8 months ago

VINC 10Q due 4/3

Monksdream

Monksdream 8 months ago

VINC 10Q due 3/25
Next day settlement 5/28 per SEC mandate

Monksdream

Monksdream 8 months ago

VINC new 52.week hi

Monksdream

Monksdream 9 months ago

VINC new 52 week high

Monksdream

Monksdream 9 months ago

VINC in the Barchart Top 10
https://www.barchart.com/stocks/performance/percent-change/advances?orderBy=percentChange&orderDir=desc

Tom turtles

Tom turtles 9 months ago

Very nice surprise...🆙⬆️

Monksdream

Monksdream 9 months ago

VINC new 52 week high

glenn1919

glenn1919 9 months ago

VINC..................................https://stockcharts.com/h-sc/ui?s=VINC&p=W&b=5&g=0&id=p86431144783

Awl416

Awl416 9 months ago

160k wall getting gobbled up

Awl416

Awl416 9 months ago

Another leg. Damn

Awl416

Awl416 9 months ago

Who’s poking it?

Monksdream

Monksdream 9 months ago

make it happen

make it happen 10 months ago

It's deficient. Failed to meet NASDAQs listing requirements. I'm expecting a reverse split in the future.

alchemytrader

alchemytrader 11 months ago

Monksdream

Monksdream 1 year ago

Delayed Upgrade Clock

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions